What AbCellera Biologics (ABCL)'s New Oncology Veteran Director Means For Shareholders

Simply Wall St.07-07

AbCellera Biologics Inc. recently appointed Lynn Seely, M.D., president and CEO of Lyell Immunopharma and former Myovant Sciences chief executive, to its Board of Directors as an independent director,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649988008?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-07-07 15:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649988008","market":"nz","top_or_hot":-1,"title":"What AbCellera Biologics (ABCL)'s New Oncology Veteran Director Means For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>AbCellera Biologics Inc. recently appointed Lynn Seely, M.D., president and CEO of Lyell Immunopharma and former Myovant Sciences chief executive, to its Board of Directors as an independent director,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/what-abcellera-biologics-abcls-new-oncology-veteran-director\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What AbCellera Biologics (ABCL)'s New Oncology Veteran Director Means For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat AbCellera Biologics (ABCL)'s New Oncology Veteran Director Means For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-07 15:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/what-abcellera-biologics-abcls-new-oncology-veteran-director><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbCellera Biologics Inc. recently appointed Lynn Seely, M.D., president and CEO of Lyell Immunopharma and former Myovant Sciences chief executive, to its Board of Directors as an independent director,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/what-abcellera-biologics-abcls-new-oncology-veteran-director\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/what-abcellera-biologics-abcls-new-oncology-veteran-director","article_id":"2649988008","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/what-abcellera-biologics-abcls-new-oncology-veteran-director","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649988008","pubTimestamp":1783409487,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"AbCellera Biologics Inc. recently appointed Lynn Seely, M.D., president and CEO of Lyell Immunopharma and former Myovant Sciences chief executive, to its Board of Directors as an independent director, adding deep experience in oncology and commercializing complex therapies.\nHer background leading drug programs from first-in-human trials through approvals and major acquisitions may influence how AbCellera shapes its pipeline priorities and commercialization plans.\nWe’ll now examine how adding...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","ABCL":"AbCellera Biologics","BK4535":"淡马锡持仓"},"translate_title":"AbCellera Biologics(ABCL)新任肿瘤学资深总监对股东意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":1.5},"content_text":"AbCellera Biologics Inc. recently appointed Lynn Seely, M.D., president and CEO of Lyell Immunopharma and former Myovant Sciences chief executive, to its Board of Directors as an independent director, adding deep experience in oncology and commercializing complex therapies. Her background leading drug programs from first-in-human trials through approvals and major acquisitions may influence how AbCellera shapes its pipeline priorities and commercialization plans. We’ll now examine how adding Dr. Seely’s late-stage development and commercialization expertise could influence AbCellera’s evolving investment narrative. AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementAbCellera Biologics Investment Narrative RecapTo own AbCellera, you need to believe its antibody discovery engine and early clinical assets can eventually support more durable revenue, despite persistent losses and a high valuation multiple. Dr. Seely’s appointment strengthens late stage and commercialization experience, but it does not materially change the near term focus on ABCL635 data and the key risk that heavy R&D spending and uneven partner revenue keep net losses elevated. The recent preclinical collaboration with Jazz Pharmaceuticals on T cell engaging multispecific antibodies is most relevant here, as it links AbCellera’s discovery platform with oncology development and commercialization expertise. While Jazz controls late stage development, this deal underscores how new board voices with oncology backgrounds may help frame expectations around milestones, royalty potential, and how platform partnerships could complement the internal pipeline as catalysts unfold. Yet while the board is adding late stage depth, investors should still be aware of the risk that AbCellera’s widening losses and lumpy revenue could... Read the full narrative on AbCellera Biologics (it's free!)AbCellera Biologics' narrative projects $40.9 million revenue and $6.4 million earnings by 2029. This assumes revenues decline by 19.8% per year and earnings increase by about $150.4 million from -$144.0 million today.Uncover how AbCellera Biologics' forecasts yield a $10.43 fair value, a 33% upside to its current price.Exploring Other PerspectivesABCL 1-Year Stock Price Chart Some of the lowest estimate analysts paint a far more cautious picture, assuming revenue could shrink toward about US$5.3 million and only modest earnings by 2029, underscoring how views on AbCellera’s reliance on uncertain milestones and royalty streams can vary widely and may shift again as the impact of Dr. Seely’s oncology experience comes into clearer focus.Explore 8 other fair value estimates on AbCellera Biologics - why the stock might be worth 11% less than the current price!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your AbCellera Biologics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.Our free AbCellera Biologics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbCellera Biologics' overall financial health at a glance.Interested In Other Possibilities?Opportunities like this don't last. These are today's most promising picks. Check them out now:The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Find 41 companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649988008","isCrawlerRequest":true}